Autolus Limited   Report issue

For profit Phase 2
Founded: London United Kingdom (2014)

Organization Overview

First Clinical Trial
2017
NCT03287804
First Marketed Drug
None
First NDA Approval
None
Last Known Activity
2020

Timeline

NOW
  • Now

Alternative names

Autolus Limited

Indications

Experimental Indications (Clinical Trials, Phases 1-4)


 

Immunoblastic Lymphadenopathy (Phase 2)

Leukemia (Phase 2)

Leukemia, Lymphoid (Phase 2)

Lymphoma (Phase 2)

Lymphoma, B-Cell (Phase 2)

Lymphoma, Large B-Cell, Diffuse (Phase 2)

Lymphoma, Large-Cell, Anaplastic (Phase 2)

Lymphoma, Non-Hodgkin (Phase 2)

Lymphoma, T-Cell (Phase 2)

Lymphoma, T-Cell, Peripheral (Phase 2)

Multiple Myeloma (Phase 2)

Neoplasms, Plasma Cell (Phase 2)

Precursor Cell Lymphoblastic Leukemia-Lymphoma (Phase 2)

Overview

  • Highest Phase: Phase 2
  • # of Trials: 6
  • # of Trial APIs: 6